Articles and Videos
Loading...
May 16, 2023
How Could a Change in Legislation Affect the Cannabinoid Industry?
InMed's VP, Sales & Marketing, Jerry P. Griffin, talks about how a change in legislation could impact the bioidentical cannabinoid manufacturing industry. In this interview,...
Source: Benzinga All Access
May 8, 2023
BayMedica’s Bioidentical Rare Cannabinoids Fill a Market Need for Large Scale Batch-to-batch Consistency
InMed's VP, Sales & Marketing, Jerry P. Griffin, talks about how the market for bioidentical rare cannabinoids has changed over the past year. Jerry contributes...
Source: Benzinga All Access
April 19, 2023
The Dales Report: InMed’s Latest Milestones Explained
InMed CEO, Eric A. Adams, joins Shadd Dales of The Dales Report to speak about InMed's latest milestones including the latest on the Phase 2...
Source: The Dales Report
March 29, 2023
Benzinga: InMed’s Subsidiary BayMedica Talks About Increased Interest in Rare Cannabinoids for Health and Wellness Products
InMed's VP, Sales & Marketing, Jerry P. Griffin, speaks with Benzinga's Zunaid Suleman. In the interview, Jerry talks about the increased interest in rare cannabinoids...
Source: Benzinga All Access
March 13, 2023
Peer-reviewed Publication: Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway
A peer-reviewed scientific study entitled “Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signalling pathway” has been published in the International...
March 9, 2023
InMed Presents at the 2023 Emerging Growth Conference
InMed’s CEO, Mr. Eric A. Adams, presents at the Emerging Growth Conference. This virtual presentation was given on March 8th, 2023. In the presentation, Mr....